ReForm Biologics, MilliporeSigma ink license agreement

By The Science Advisory Board staff writers

February 10, 2020 -- ReForm Biologics and MilliporeSigma have signed a licensing agreement to develop and market excipients used for biotherapeutic applications.

The agreement dictates that the two firms will research and develop ReForm Biologics' excipients for pharmaceutical use, with MilliporeSigma funding the effort and taking responsibility for global marketing, manufacturing, and sale of the excipients to its customers. ReForm Biologics will receive revenues from MilliporeSigma for sublicensing ReForm Biologics' technology, it said.

Agilent to fund biotherapy incubator in India
Agilent Technologies has announced a partnership with the Indian Institute of Technology Delhi to advance biotherapeutic research in the country.
MilliporeSigma licenses CRISPR tech to Promega
MilliporeSigma announced on December 19 that it has signed a license agreement providing Promega Corp., access to MilliporeSigma's foundational CRISPR...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
2020 ACCP Annual Meeting
September 20-22
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter